Track topics on Twitter Track topics that are important to you
AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
Original Article: AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid studyNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...